LOG IN
SIGN UP
MARKET
INCY
INCY
Incyte Corp
NASDAQ
Real-time Quotes | Nasdaq Last Sale
77.19
+1.17
+1.54%
After Hours: 77.15 -0.04 -0.05% 17:00 05/27 EDT
OPEN
76.45
PREV CLOSE
76.02
HIGH
77.34
LOW
75.80
VOLUME
1.15M
TURNOVER
0
52 WEEK HIGH
88.26
52 WEEK LOW
61.91
MARKET CAP
17.10B
P/E (TTM)
18.37
1D
5D
1M
3M
1Y
5Y
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
WILMINGTON, Del., May 26, 2022--Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
Business Wire · 2d ago
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del., May 24, 2022--Incyte (Nasdaq:INCY) announced today that it will present at the 43rd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 14, 2022 at 8:00 a.m. (PDT) /11 a.m. (EDT) in Rancho Palos Verdes.
Business Wire · 3d ago
Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata
The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.
Zacks · 4d ago
CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss
Benzinga · 05/20 18:53
Eli Lilly Gets Positive Opinion for Olumiant in Europe. The Stock Rises.
Dowjones · 05/20 18:06
Lilly, Incyte's Olumiant get EMA panel nod for hair loss disorder alopecia areata
A committee of the European Medicines Agency (EMA) recommended the approval of Eli Lilly (NYSE:LLY) and Incyte's (NASDAQ:INCY) Olumiant to treat adults with severe alopecia areata (AA). Olumiant is already approved in the
Seekingalpha · 05/20 13:56
BRIEF-CHMP Recommends Approval Of Lilly And Incyte's Olumiant As Severe Alopecia Areata Treatment
reuters.com · 05/20 12:47
CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for OLUMIANT® (baricitinib) for the treatment of adult...
PR Newswire · 05/20 12:11
No Data
Learn about the latest financial forecast of INCY. Analyze the recent business situations of Incyte Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 18 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
27.78%Strong Buy
38.89%Buy
27.78%Hold
5.56%Under-perform
0.00%Sell
Analyst Price Target
The average INCY stock price target is 92.00 with a high estimate of 124.00 and a low estimate of 58.00.
Current 77.19
EPS
Actual
Estimate
0.290.590.881.18
Institutional Holdings
Institutions: 798
Institutional Holdings: 225.84M
% Owned: 101.96%
Shares Outstanding: 221.51M
TypeInstitutionsShares
Increased
181
19.77M
New
67
2.19M
Decreased
188
15.42M
Sold Out
57
2.96M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/President/Chief Executive Officer/Director
Herve Hoppenot
Chief Financial Officer/Executive Vice President
Christiana Stamoulis
Executive Vice President/Chief Scientific Officer
Dashyant Dhanak
Executive Vice President/General Counsel
Maria Pasquale
Executive Vice President/General Manager
Jonathan Dickinson
Executive Vice President/Director of Human Resources
Paula Swain
Executive Vice President
Barry Flannelly
Executive Vice President
Vijay Iyengar
Executive Vice President
Michael Morrissey
Executive Vice President
Steven Stein
Lead Director/Independent Director
Julian Baker
Director
Otis Brawley
Independent Director
Jean-Jacques Bienaime
Independent Director
Paul Clancy
Independent Director
Wendy Dixon
Independent Director
Jacqualyn Fouse
Independent Director
Edmund Harrigan
Independent Director
Katherine High
No Data
No Data
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.
Webull offers kinds of Incyte Corporation stock information, including NASDAQ:INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.